Last $3.62 USD
Change Today -0.03 / -0.82%
Volume 2.7M
SQNM On Other Exchanges
Symbol
Exchange
NASDAQ GS
Frankfurt
As of 8:10 PM 03/5/15 All times are local (Market data is delayed by at least 15 minutes).

sequenom inc (SQNM) Snapshot

Open
$3.65
Previous Close
$3.65
Day High
$3.83
Day Low
$3.58
52 Week High
12/3/14 - $4.19
52 Week Low
03/27/14 - $2.25
Market Cap
424.9M
Average Volume 10 Days
1.0M
EPS TTM
$-0.22
Shares Outstanding
117.4M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for SEQUENOM INC (SQNM)

sequenom inc (SQNM) Related Businessweek News

View More BusinessWeek News

sequenom inc (SQNM) Details

Sequenom, Inc., a life sciences company, provides genomic and genetic analysis solutions for the molecular diagnostic and clinical research markets in the United States and internationally. It operates through two segments, Sequenom Center for Molecular Medicine and Sequenom Bioscience. The Sequenom Center for Molecular Medicine segment provides molecular based, laboratory developed tests (LDTs) with a focus principally on prenatal diseases and conditions, and ophthalmological diseases and conditions. Its LDTs include MaterniT21 PLUS LDT, a noninvasive prenatal test (NIPT) to detect fetal chromosomal abnormalities; HerediT CF LDT, a carrier screen test to identify individuals with cystic fibrosis or genetic mutations; SensiGene RHD LDT, a NIPT to determine the presence or absence of fetal Rhesus D factor; and RetnaGene AMD LDT, a genetic test to predict the risk of a patient with dry or early stage age-related macular degeneration. The Sequenom Bioscience segment provides technology and research use only tools, such as the MassARRAY System platform, chip and reagent consumables, software, and biomarker assay panels for genetic analysis and applications in translational research, clinical research, pharmacogenomics, oncology, and agricultural genomics. Its MassARRAY systems are used in a range of DNA/RNA analysis applications, including SNP, genotyping, detection of mutations, analysis of copy number variants, and other structural genome variations, as well as in quantitative gene expression analysis, quantitative DNA methylation analysis, comparative sequence analysis of haploid organisms, SNP discovery, and oligonucleotide quality control. This segment also provides contract research services to clinical research laboratories, bioagriculture, biotechnology and pharmaceutical companies, academic institutions, and government agencies. The company was founded in 1994 and is headquartered in San Diego, California.

570 Employees
Last Reported Date: 02/27/14
Founded in 1994

sequenom inc (SQNM) Top Compensated Officers

Chief Executive Officer, President and Direct...
Total Annual Compensation: $400.0K
Chief Scientific and Strategy Officer
Total Annual Compensation: $375.0K
Consultant
Total Annual Compensation: $354.3K
Compensation as of Fiscal Year 2013.

sequenom inc (SQNM) Key Developments

Sequenom Inc. Reports Unaudited Consolidated Earnings Results for the Fourth Quarter and Year Ended December 31, 2014

Sequenom Inc. reported unaudited consolidated earnings results for the fourth quarter and year ended December 31, 2014. For the quarter, the company reported total revenues of $36.8 million, an increase of 13% compared to revenues of $32.7 million for the fourth quarter of 2013. This increase in total revenues is primarily due to a higher volume of MaterniT21 PLUS tests performed. Operating income was $20.0 million as compared to a loss of $19.2 million, for the same period in 2013. Net earnings were $18.3 million or $0.14 per diluted share, as compared to a net loss of $18.9 million, or $0.16 per share, for the same period in 2013. This improvement in net earnings is due to the reduced loss from operations and the gain related to the Illumina transaction. Earnings from continuing operations before income taxes was $17,982,000 compared to loss from continuing operations before income taxes of $21,272,000 a year ago. Income from operations was $16,747,000 compared to loss from continuing operation of $19,722,000 a year ago. For the year, the company’s total revenues were $151.6 million, compared to $119.6 million for the prior year 2013, a 27% increase. Revenues are recorded primarily on a cash basis, with 44% of revenue in the fourth quarter of 2014 accounted for on the accrual basis of accounting. Net earnings were $1.0 million, or $0.01 per share, compared to a net loss of $107.4 million for 2013, or $0.93 per share. Loss from continuing operations before income taxes was $22,040,000 compared to loss from continuing operations before income taxes of $110,920,000 a year ago. Loss from operations was $14,364,000 compared to $109,567,000 a year ago. Net cash used in operating activities was $28,086,000 compared to $88,095,000 a year ago. This reduction in cash used in operating activities is primarily due to the increase in revenue and decrease in operating expenses. Purchases of property, equipment and leasehold improvements were $2,236,000 compared to $12,071,000 a year ago. Payment for the purchase of intangible assets was $9,250,000. Net loss from continuing operations improved by 87% to $14.4 million, or $0.12 per share as compared to $109.6 million, or $0.95 per share for 2013. The improvement in the loss from continuing operations from prior year is due to improved gross margins, reduced operating expenses and a gain on the pooled patents agreement with Illumina.

Sequenom Inc. Presents at Biocom's Global Life Science Partnering Conference, Feb-25-2015

Sequenom Inc. Presents at Biocom's Global Life Science Partnering Conference, Feb-25-2015 . Venue: The Lodge at Torrey Pines, 11480 North Torrey Pines Road, La Jolla, CA 92037, United States.

Sequenom Inc. to Report Q4, 2014 Results on Mar 04, 2015

Sequenom Inc. announced that they will report Q4, 2014 results at 5:00 PM, Eastern Daylight on Mar 04, 2015

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
SQNM:US $3.62 USD -0.03

SQNM Competitors

Market data is delayed at least 15 minutes.

Company Last Change
AtriCure Inc $17.72 USD +0.32
Cerus Corp $4.45 USD -0.01
Luminex Corp $15.62 USD -0.27
Pacific Biosciences of California Inc $6.39 USD +0.03
STAAR Surgical Co $7.14 USD -0.17
View Industry Companies
 

Industry Analysis

SQNM

Industry Average

Valuation SQNM Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 2.2x
Price/Book NM Not Meaningful
Price/Cash Flow NM Not Meaningful
TEV/Sales 1.1x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact SEQUENOM INC, please visit www.sequenom.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.